匹伐他汀与考来替米在日本糖尿病合并高脂血症及代谢综合征患者中的疗效比较。
Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome.
作者信息
Kato T, Inagaki K, Sawai Y, Kanayama H, Katada N, Itoh M
机构信息
Department of Internal Medicine Aichi Koseiren Toyotakousei Hospital, Japan.
出版信息
Exp Clin Endocrinol Diabetes. 2011 Oct;119(9):554-8. doi: 10.1055/s-0031-1273770. Epub 2011 Apr 6.
The present study was undertaken to compare the efficacy of pitavastatin and colestimide in patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. 48 diabetic patients with metabolic syndrome were randomly assigned to a pitavastatin group or colestimide group. The clinical parameters, serum lipids, fasting (FPG) and postprandial plasma glucose(PPG), HOMA-IR, hemoglobin A1c(HbA1c), hs-CRP and urinary albumin were measured before/after 24-week administration. Treatment with pitavastatin reduced LDL-C and TG, while that with colestimide significantly reduced waist circumference, BMI, LDL-C, HbA1c, FPG, PPG, HOMA-R , hs-CRP and urinary albumin. Percent improvement in LDL-C was greater in the pitavastatin group than in the colestimide group. Colestimide appeared to be useful in the management of Japanese patients with diabetes mellitus complicated by metabolic syndrome, since it alleviates obesity and insulin resistance in addition to exhibiting lipid profile-improving effects, and can thus improve markers of atherosclerosis.
本研究旨在比较匹伐他汀和考来替米特对糖尿病合并高脂血症及代谢综合征患者的疗效。48例患有代谢综合征的糖尿病患者被随机分为匹伐他汀组或考来替米特组。在给药24周前后测量临床参数、血脂、空腹血糖（FPG）和餐后血糖（PPG）、HOMA-IR、糖化血红蛋白（HbA1c）、超敏C反应蛋白（hs-CRP）和尿白蛋白。匹伐他汀治疗可降低低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG），而考来替米特治疗可显著降低腰围、体重指数（BMI）、LDL-C、HbA1c、FPG、PPG、HOMA-R、hs-CRP和尿白蛋白。匹伐他汀组LDL-C的改善百分比高于考来替米特组。考来替米特似乎对日本糖尿病合并代谢综合征患者的治疗有用，因为它除了具有改善血脂谱的作用外，还能减轻肥胖和胰岛素抵抗，从而改善动脉粥样硬化标志物。
Zotero 插件